CAPZA Private Debt arranges financing to support Columna Capital’s acquisition of Evidenze Group.
Evidenze Group is a full-service CRO supporting pharmaceutical, biotech and healthcare clients in over 20 countries with complementary services across the clinical development value chain, from early-stage clinical trials through to product commercialisation. Evidenze operates across three core business lines — Clinical Research Services, Scientific Services and Digital Health Services — and serves over 270 active clients, including global pharmaceutical companies, mid-sized biotech firms and non-commercial sponsors.
Since its inception, the Group has experienced strong growth driven by an active buy-and-build strategy, completing multiple acquisitions and expanding its footprint across Spain, Germany, Italy and Portugal; together with organic growth. Today, Evidenze employs more than 450 professionals across Europe.
With the support of Columna Capital, Evidenze aims to accelerate its growth trajectory by further consolidating a fragmented European CRO market, pursuing additional acquisitions and strengthening its service offering, while continuing to invest in talent and operational excellence.
cloud technology axon
Managed by MCH, the fund has a target size of €500 million and focus...
Capital-Riesgo.es
Subscribe to our newsletter and stay up to date with the latest news and deals!
2013 © Capital-Riesgo.es - Site Developments SL. All Rights Reserved. Terms of Service | Privacy Policy
Articles
Directory
